Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    15-September-2000      
Issue 155 Next Update - 14:00 UTC 08:00 EST    16-September-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya Today In Vidyya sm

Newsletter Summary For 15-September-2000:

The National Heart, Lung, and Blood Institute (NHLBI) has launched a 10-year, multicenter study to find new ways of detecting heart disease early, before it produces symptoms. The $68 million Multi-Ethnic Study of Atherosclerosis (MESA) will involve six centers, which will recruit 6,500 participants aged 45 to 84. Half of the participants will be men and half women. None of the participants will have known heart disease at the time of their enrollment in the study.

In other news, the Food and Drug Administration (FDA) has developed a Web site for displaying photographs and/or illustrations of breast implant complications. While the website is not intended to be photographic representation of all breast implant complications, the FDA plans to continue to add photographs and/or illustrations of complications associated with saline-filled and silicone gel-filled implants as they become available.

Vidyya has a copy of the FDA's new handbook for patients regarding breast implants. This handbook contains the latest information about breast implants to assist patients in making an informed decision about whether or not to have breast implants. It includes topics such as availability of breast implants, potential risks, answers to the most frequently asked questions by consumers, reporting of serious problems, chronology of FDA activities related to breast implants, and breast implant resource groups.

In drug news, Pfizer Inc said today that a new clinical study shows one single dose of Zithromax® (azithromycin for oral suspension) is as effective as Augmentin® (amoxicillin/clavulanate potassium), administered twice a day for 10 days, in treating acute otitis media in children.

Money talks. According to new government charts, hospitals charge an average of $34,000 to $68,000 for the 10 most expensive conditions in inpatients, exclusive of physician and other professional fees, rehabilitation costs or expenses for follow-up and home health services, according to the U.S. Agency for Healthcare Research and Quality (AHRQ).

The articles in today's Vidyya are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.